Atrasentan + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Nephropathy
Conditions
Diabetic Nephropathy
Trial Timeline
May 17, 2013 → Mar 29, 2018
NCT ID
NCT01858532About Atrasentan + Placebo
Atrasentan + Placebo is a phase 3 stage product being developed by AbbVie for Diabetic Nephropathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT01858532. Target conditions include Diabetic Nephropathy.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Nephropathy were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01858532 | Phase 3 | Terminated |
| NCT01399580 | Phase 2 | Completed |
| NCT01356849 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetic Nephropathy